Terms: = Lung cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC AND Staging
3 results:
1. MiR-587 acts as an oncogene in non-small-cell lung carcinoma via reducing cyld expression.
Li XJ; Chen LW; Gao P; Jia YJ
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12741-12747. PubMed ID: 33378022
[TBL] [Abstract] [Full Text] [Related]
2. A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer.
Lee GD; Kim DK; Moon DH; Joo S; Hwang SK; Choi SH; Kim HR; Kim YH; Park SI
Eur J Cardiothorac Surg; 2016 Feb; 49(2):580-8. PubMed ID: 25890940
[TBL] [Abstract] [Full Text] [Related]
3. Classifications of n2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodes.
Ito M; Yamashita Y; Tsutani Y; Misumi K; Harada H; Miyata Y; Okada M
Clin Lung Cancer; 2013 Nov; 14(6):651-7. PubMed ID: 24188630
[TBL] [Abstract] [Full Text] [Related]
